

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 7/06</b>		A1	(11) International Publication Number: <b>WO 95/24884</b> (43) International Publication Date: 21 September 1995 (21.09.95)
(21) International Application Number: PCT/US95/02898		(74) Agents: RICHARDS, John; Ladas & Parry, 26 West 61st Street, New York, NY 10023 (US) et al.	
(22) International Filing Date: 10 March 1995 (10.03.95)		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN. European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).	
(30) Priority Data: 213,931 16 March 1994 (16.03.94) US		(71) Applicant (for all designated States except US): HANDELMAN, Joseph, H. [US/US]; 26 West 61st Street, New York, NY 10023 (US).	
(60) Parent Application or Grant (63) Related by Continuation US 213,931 (CON) Filed on 16 March 1994 (16.03.94)		(72) Inventors; and (75) Inventors/Applicants (for US only): AHLUWALIA, Gurpreet, S. [US/US]; 8632 Stable View Court, Gaithersburg, MD 20879 (US). SHANDER, Douglas [US/US]; 16112 Howard Landing Drive, Gaithersburg, MD 20878 (US). HENRY, James, P. [US/US]; 6776 Wood Duck Court, Frederick, MD 21701 (US).	

(54) Title: INHIBITION OF HAIR GROWTH

(57) Abstract

Mammalian hair growth is reduced by applying to the skin an inhibitor of nitric oxide synthetase.

IPS

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

INHIBITION OF HAIR GROWTH

The invention relates to a method of reducing unwanted hair growth in mammals.

A main function of mammalian hair is 5 to provide environmental protection. However, that function has largely been lost in humans, in whom hair is kept or removed from various parts of the body essentially for cosmetic reasons. For example, it is generally preferred 10 to have hair on the scalp but not on the face.

Various procedures have been employed to remove unwanted hair, including shaving, electrolysis, depilatory creams or lotions, waxing, plucking, and other cosmetic procedures, 15 and therapeutic antiandrogens. These conventional procedures generally have drawbacks associated with them. Shaving, for instance, can cause nicks and cuts, and can leave a perception of an increase in the rate of hair 20 regrowth. Shaving also can leave an undesirable stubble. Electrolysis, on the other hand, can keep a treated area free of hair for prolonged periods of time, but can be expensive and painful, and it sometimes causes scarring. 25 Depilatory creams, though effective, typically are not recommended for frequent use due to their high irritancy potential. Waxing and

- 2 -

plucking can cause pain, discomfort, in-grown hairs, and poor removal of short hair. Finally, antiandrogens -- which have been used to treat female hirsutism -- can have unwanted side effects.

It has previously been disclosed that the rate and character of hair growth can be altered by applying to the skin inhibitors of certain enzymes. These inhibitors include 10 inhibitors of 5-alpha reductase, ornithine decarboxylase, S-adenosylmethionine decarboxylase, gamma-glutamyl transpeptidase, and transglutaminase. See, for example, Breuer et al., U.S. Pat. No. 4,885,289; Shander, U.S. 15 Pat. No. 4,720,489; Ahluwalia, U.S. Pat. No. 5,095,007; Ahluwalia et al., U.S. Pat. No. 5,096,911; Shander et al., U.S. Pat. No. 5,132,293; and Shander et al., U.S. Pat. No. 5,143,925.

20 Nitric oxide synthetase forms nitric oxide by oxidizing one of the two terminal guanido nitrogens in L-arginine. The nitric oxide formed by the action of this enzyme is implicated in diverse physiological functions, 25 including smooth muscle relaxation, immune system regulation, and neurotransmission.

It has now been found that unwanted mammalian (including human) hair growth, particularly androgen-stimulated hair growth, 30 can be inhibited by topical application of an inhibitor of nitric oxide synthetase to the skin. The unwanted hair growth which is reduced may be normal hair growth which is cosmetically reduced, or hair growth that results from an 35 abnormal or diseased condition.

Preferred inhibitors of nitric oxide synthetase include N<sup>G</sup>-methyl-L-arginine, N<sup>G</sup>-

- 3 -

nitro-L-arginine, N<sup>G</sup>-nitro-L-arginine methyl ester, N<sup>G</sup>-nitro-L-arginine benzyl ester, N-acetyl-L-arginine, N<sup>G</sup>-amino-L-arginine, N-benzoyl-L-arginineamide, N-benzoyl-L-arginine methyl ester, N-benzoyl-L-arginine ethyl ester, N<sup>G</sup>-allyl-L-arginine, N<sup>G</sup>-cyclopropyl-L-arginine, N-iminoethyl-L-ornithine, L-homoarginine, L-argininamide, diphenyleneiodonium, iodonium-diphenyl, and di-2-thienyliodonium.

Irreversible inhibitors of nitric oxide synthetase are preferred, although reversible inhibitors (competitive and non-competitive) also can be used.

The inhibitor of nitric acid synthetase preferably is incorporated in a topical composition or a cosmetic composition which includes a non-toxic dermatologically acceptable vehicle or carrier which is adapted to be spread upon the skin. Examples of suitable vehicles are acetone, alcohols, or a cream, lotion, or gel which can effectively deliver the active compound. One such vehicle is disclosed in co-pending application PCT/US 93/05068. In addition, a penetration enhancer may be added to the vehicle to further enhance the effectiveness of the formulation.

The concentration of the nitric oxide synthetase inhibitor in the composition may be varied over a wide range up to a saturated solution, preferably from 0.1% to 30% by weight or even more; the reduction of hair growth increases as the amount of inhibitor applied increases per unit area of skin. The maximum amount effectively applied is limited only by the rate at which the inhibitor penetrates the skin. Generally, the effective amounts range from 100 to 3000 micrograms or more per square

- 4 -

centimeter of skin.

The composition should be topically applied to a selected area of the body from which it is desired to inhibit hair growth. For 5 example, the composition can be applied to the face, particularly to the beard area of the face, i.e., the cheek, neck, upper lip, and chin. The composition can also be applied to the legs, arms, torso or armpits. The 10 composition is particularly suitable for inhibiting the growth of unwanted hair in women suffering from hirsutism or other conditions. In humans, the composition should be applied once or twice a day, or even more frequently, 15 for at least three months to achieve a perceived reduction in hair growth. Reduction in hair growth is demonstrated when the frequency or hair removal is reduced, or the subject perceives less hair on the treated site, or 20 quantitatively, when the weight of hair removed by shaving (i.e., hair mass) is reduced.

Male intact Golden Syrian hamsters are considered acceptable models for human beard hair growth in that they display oval shaped 25 flank organs, one on each side, each about 8 mm. in major diameter, which grow thick black and coarse hair similar to human beard hair. These organs produce hair in response to androgens in the hamster. To evaluate the effectiveness of a 30 particular nitric oxide synthetase inhibitor, the flank organs of each of a group of hamsters are depilated by applying a thioglycolate based chemical depilatory (Surge). To one organ of each animal 10  $\mu$ l. of vehicle alone once a day 35 is applied, while to the other organ of each animal an equal amount of vehicle containing a nitric oxide synthetase inhibitor is applied.

- 5 -

After thirteen applications (one application per day for five days a week), the flank organs are shaved and the amount of recovered hair (hair mass) from each is weighed. Percent-reduction 5 of hair growth is calculated by subtracting the hair mass (mg) value of the test compound treated side from the hair mass value of the vehicle treated side; the delta value obtained is then divided by the hair mass value of the 10 vehicle treated side, and the resultant number is multiplied by 100.

The above-described assay will be referred to herein as the "Golden Syrian hamster" assay. Preferred compositions provide 15 an inhibition in hair growth of at least about 35%, more preferably at least about 50%, and most preferably at least about 70%, when tested in the Golden Syrian hamster assay.

A number of nitric oxide synthetase 20 inhibitors were tested in the Golden Syrian hamster assay. The results are presented in Table 1.

TABLE 1

Compound	Dose	Vehicle	pH	Treated		Percent Inhibition (mean $\pm$ SEM)
				(mg)	Control (mg)	
$N^G$ -methyl-L-arginine	20%	A	8.0	0.534 $\pm$ 0.06	2.291 $\pm$ 0.15	76.72 $\pm$ 2.63
$N^G$ -nitro-L-arginine methyl ester	10%	A	7.0	0.964 $\pm$ 0.17	2.765 $\pm$ 0.32	63.49 $\pm$ 6.41
$N^G$ -nitro-L-arginine methyl ester	20%	A	6.5	0.486 $\pm$ 0.13	2.856 $\pm$ 0.24	83.26 $\pm$ 2.76
$N^G$ -nitro-L-arginine benzyl ester	15%	A	7.0	1.045 $\pm$ 0.11	2.334 $\pm$ 0.12	54.70 $\pm$ 4.87
$N\alpha$ -acetyl-L-arginine	10%	A	4.0	1.274 $\pm$ 0.20	1.936 $\pm$ 0.09	33.12 $\pm$ 11.0
$N\alpha$ -benzoyl-L-arginine	5%	B	5.0	1.385 $\pm$ 0.16	2.391 $\pm$ 0.37	39.62 $\pm$ 4.02
$N\alpha$ -benzoyl-L-arginin- amide	15%	B	7.0	1.031 $\pm$ 0.11	1.973 $\pm$ 0.20	46.22 $\pm$ 5.03
$N\alpha$ -benzoyl-L-arginine methyl ester	15%	B	7.0	1.306 $\pm$ 0.21	2.656 $\pm$ 0.21	51.28 $\pm$ 8.26
L-homoarginine	20%	A	5.5	1.189 $\pm$ 0.13	1.918 $\pm$ 0.13	37.79 $\pm$ 5.01
L-argininamide	20%	A	5.0	0.669 $\pm$ 0.15	2.329 $\pm$ 0.23	67.69 $\pm$ 8.75

Vehicle A: Pure water (68%), ethanol (16%), propylene glycol (5%), dipropylene glycol (5%),  
benzyl alcohol (4%) and propylene carbonate (2%)

Vehicle B: Pure water (80%), ethanol (10%) and propylene glycol (10%)

- 7 -

The following assay measures the activity of nitric oxide synthetase in hair follicles. The assay can be used to evaluate the effectiveness of nitric oxide synthetase 5 inhibitors in reducing nitric oxide synthetase activity.

Hair follicles from hamster flank organ were excised, and an enzyme extract was prepared in buffered sucrose solution, pH 7.4, 10 using a sonicator device. The sonicated extracts were centrifuged at 12,000 x g, and the clarified supernatant was analyzed for nitric oxide synthetase activity. Specifically, 50  $\mu$ l of follicle supernatant were added to 150  $\mu$ l of 15 an assay mixture containing 100 mM tris buffer (pH 7.5), 50  $\mu$ M cold arginine, 1  $\mu$ Ci/ml [ $^3$ H]-arginine, 3 mM CaCl<sub>2</sub>, and 1 mM NADPH warmed to 37°C., and incubated for 30 minutes at 37°C. Formation of the radiolabelled citrulline, a 20 coproduct of nitric oxide synthetase action that can be used to provide a measure of the enzyme activity, was determined using an HPLC methodology capable of separating citrulline from arginine.

25 More specifically, after termination of the enzyme reaction by heating at 95°C. for 5 min, the reaction mixture was centrifuged at 12,000 x g for 2 min. A 100  $\mu$ l aliquot of the clarified supernatant containing reaction 30 products was injected onto a cation exchange column (10  $\mu$  Partisil 10-SAX 25 cm x 4.6 mm), and then eluted with 0.02 M monobasic potassium phosphate buffer (pH 4.5). Under these 35 conditions the elution time of citrulline and arginine are 6 and 7 min, respectively. The HPLC effluent was collected in 1.0 ml fractions and the amount of radiolabelled citrulline

- 8 -

formed in the assay was determined by scintillation counting. The enzyme activity was linear with respect to hair follicle extract added (i.e., protein concentration), as well as 5 the time of incubation.

Inhibitors of nitric oxide synthetase were evaluated as follows. Inhibitors at a final concentration of 1.0 mM were preincubated with the hair follicle enzyme extract (the 10 supernatant). The enzyme activity following exposure to the inhibitor was assayed as described above. This assay will be referred to herein as the "hair follicle nitric oxide synthetase inhibition assay." The results are 15 provided in Table 2.

TABLE 2

		Inhibition of Hair Follicle Nitric Oxide Synthetase Activity
20	<u>Test Compound</u>	
	$N^G$ -methyl-L-arginine	100%
	$N^G$ -nitro-L-Arginine	96%
	$N^G$ -nitro-L-arginine methyl ester	30%
	$N^G$ -nitro-L-arginine benzyl ester	55%
25	$\text{Na-} \alpha$ -acetyl-L-arginine	39%
	$\text{Na-} \alpha$ -benzoyl-L-argininamide	100%
	$\text{Na-} \alpha$ -benzoyl-L-arginine methyl ester	100%
	$\text{Na-} \alpha$ -benzoyl-L-arginine ethyl ester	100%
	L-homoarginine	57%
30	L-argininamide	98%

It will be appreciated by those skilled in the art that the invention can be performed within a wide range of equivalent parameters of composition and conditions without 35 departing from the spirit or scope of the invention or of any embodiment thereof.

- 9 -

C L A I M S

1. A method of inhibiting mammalian hair growth which comprises
  - 5 selecting an area of skin of a mammal from which reduced hair growth is desired; and
  - 10 applying to said area of skin an inhibitor of nitric oxide synthetase in an amount effective to reduce hair growth.
2. The method of claim 1, wherein said inhibitor is N<sup>G</sup>-methyl-L-arginine, N<sup>G</sup>-nitro-L-arginine, N<sup>G</sup>-nitro-L-arginine methyl ester, N<sup>G</sup>-nitro-L-arginine benzyl ester, N $\alpha$ -acetyl-L-arginine, N $\alpha$ -benzoyl-L-arginine, N $\alpha$ -benzoyl-L-argininamide, N $\alpha$ -benzoyl-L-arginine methyl ester, L-homoarginine or L-argininamide.
- 15 3. The method of claim 1, wherein said inhibitor is an irreversible inhibitor.
4. The method of claim 1, wherein said inhibitor is applied as part of a composition comprising a dermatologically acceptable vehicle.
- 20 5. The method of claim 4, wherein the concentration of said inhibitor in said composition is between 1% and 30%.
- 25 6. The method of claim 4, wherein the composition provides a reduction in hair growth of at least 30%, preferably at least 50%, more preferably at least 70%, when tested in the Golden Syrian hamster assay.
- 30 7. The method of claim 1, wherein said inhibitor is applied to the skin in an amount of from 100 to 3000 micrograms of said inhibitor per square centimeter of skin.
- 35 8. The method of claim 1, wherein said inhibitor when tested in the hair follicle nitric oxide synthetase inhibition assay inhibits nitric oxide synthetase activity by at

- 10 -

least 30%.

9. The method of claim 1, wherein said mammal is a human.

10. The method of claim 1, wherein said 5 area of skin is on the face, a leg, an arm, an armpit or the torso of the human.

11. A method according to any one of claims 1 to 10, wherein said applying of said inhibitor has a cosmetic effect.

10 12. A method of producing a composition for inhibiting mammalian hair growth, which comprises selecting an inhibitor of nitric oxide synthetase, and combining said inhibitor, in an amount effective to reduce hair growth, with a 15 non-toxic, dermatologically acceptable vehicle or carrier.

13. A method according to claim 12, wherein said vehicle or carrier is adapted to be spread upon the skin of a mammal.

20 14. A method according to claim 12, wherein a cosmetic composition is produced.

15. A method according to claim 12, wherein said inhibitor is as defined in any one of claims 2 to 8.

25 16. The new use of an inhibitor of nitric oxide synthetase for reducing hair growth.

17. A composition when used for inhibiting mammalian hair growth, which includes an inhibitor of nitric oxide synthetase in an 30 amount effective to reduce hair growth, and a non-toxic, dermatologically acceptable vehicle or carrier.

18. A composition according to claim 17, wherein said inhibitor is as defined in any one 35 of claims 2 to 8.

19. A composition according to claim 17, which is a cosmetic composition.

# INTERNATIONAL SEARCH REPORT

Internal Application No  
PCT/US 95/02898

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K7/06

According to International Patent Classification (IPC) or to both national classification and IPC:

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,86 02269 (HANDELMAN, JOSEPH, H) 24 April 1986 cited in the application	1

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

### Special categories of cited documents:

- A document defining the general state of the art which is not considered to be of particular relevance
- B earlier document but published on or after the international filing date
- C document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- D document referring to an oral disclosure, use, exhibition or other means
- E document published prior to the international filing date but later than the priority date claimed

Later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

5 July 1995

Date of mailing of the international search report

14.07.95

Name and mailing address of the ISA

European Patent Office, P.O. Box 8040  
D-8033 Munich 80  
Tel. (0 89) 59 00 20 00, Telex 631 635 EPOM  
Fax (0 89) 59 1 300-3016

Authorized officer

Luyten, H

**INTERNATIONAL SEARCH REPORT**

Internat Application No  
PCT/US 95/02898

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-8602269	24-04-86	US-A- 4720489	19-01-88
		AU-B- 590730	16-11-89
		AU-A- 4867385	02-05-86
		CA-A- 1262335	17-10-89
		DE-A- 3585526	09-04-92
		EP-A,B 0198893	29-10-86
		JP-B- 6053680	20-07-94
		JP-T- 62500932	16-04-87
		NO-B- 174832	11-04-94